By redefining CD4+CD8a+ T cell as key effectors in lung repair and demonstrating nanotechnology-enhanced cytokine delivery, we established a template for biomimetic therapeutics in ARDS management. The gene discussed is CD8A; the disease is acute respiratory distress syndrome.